EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation

Jie Xu, Joseph M Pickard, Gabriel Núñez

Cell Reports · 2024-08 · 43 (8) · 114609

DOI: 10.1016/j.celrep.2024.114609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024-08. Verfasst von Jie Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: jiexu@med.umich…. Hauptthemen laut MEDLINE: Disulfiram, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Lipoylation. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DisulfiramNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesLipoylationUnited States Food and Drug AdministrationAnimalsHumansMiceMice, Inbred C57BLUnited StatesCaspase 1HEK293 CellsDrug ApprovalPyroptosis

Stichwörter der Autor:innen

CP: ImmunologyNLRP3disulfiramgasdermin Dinflammasomepalmitoylation

Substanzen

DisulfiramNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNlrp3 protein, mouseCaspase 1

Autor:innen und Institutionen

  • Department of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: jiexu@med.umich.edu.
  • Department of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Department of Pathology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: gabriel.nunez@umich.edu.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Xu, J., Pickard, J. M., & Núñez, G. (2024). FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation. Cell Reports, 43(8), 114609. https://doi.org/10.1016/j.celrep.2024.114609

Vancouver

Xu J, Pickard JM, Núñez G. FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation. Cell Reports. 2024;43(8):114609. doi:10.1016/j.celrep.2024.114609

BibTeX
@article{Xu2024,
  author = {Xu, Jie and Pickard, Joseph M and Núñez, Gabriel},
  title = {FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation},
  journal = {Cell Reports},
  year = {2024},
  volume = {43},
  number = {8},
  pages = {114609},
  doi = {10.1016/j.celrep.2024.114609}
}
Kostenlos starten →